First-line Therapy for NSCLC: Is Amivantamab-Lazertinib better than Osimertinib?

被引：0
|
作者：
Simon, Annika
机构：
来源：
PNEUMOLOGIE | 2024年 / 78卷 / 12期
关键词：
D O I：
10.1055/a-2372-8278
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Amivantamabine combination with lazertinib was associated with clinically meaningful antitumor activity in patients with previously untreated or osimertinib-pretreated advanced non-small cell lung cancer (NSCLC) with EGFR mutation. Cho et al. now wanted to further examine the progression-free survival benefit of this combination compared to osimertinib and have initiated a phase III study.
引用
收藏
页数：1
相关论文
共 50 条
  • [1] MARIPOSA: Randomized Phase 3 Study of First-line Amivantamab plus Lazertinib vs Osimertinib vs Lazertinib in EGFR-mutant NSCLC
    Shreeve, S. M.
    Martinez, M.
    Verheijen, R. B.
    Xie, J.
    Sun, T.
    Haddish-Berhane, N.
    Curtin, J. C.
    Karkera, J.
    Pang, D.
    Roshak, A.
    Knoblauch, R. E.
    Patel, K.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S620 - S621
  • [2] Amivantamab Plus Lazertinib vs Osimertinib in First Line, EGFR-Mutant Advanced NSCLC: Patientrelevant Outcomes from MARIPOSA
    Nguyen, D.
    Besse, B.
    Cho, B. C.
    Lee, S. -H.
    Lee, K. H.
    Lu, S.
    Cheng, Y.
    Yao, Y.
    Girard, N.
    Lin, C. -C.
    Felip, E.
    Aguilar, A.
    Charoentum, C.
    Cruz, F. J. S. M.
    Majem, M.
    Lim, C. S.
    Akamatsu, H.
    Hayashi, H.
    Yang, J. C. -H.
    Kowalyszyn, R.
    Tiscoski, K.
    Franke, F.
    Ponomarenko, D.
    Arslan, C.
    Forster, M.
    Urban, D.
    Misch, D.
    Delmonte, A.
    Montes, L. V. G.
    Gadgeel, S. M.
    Cruz-Correa, M.
    Peguero, J.
    Rousey, S.
    Gaffar, Y.
    Owen, S.
    Schuchard, J.
    Diels, J.
    Sermon, J.
    Sun, T.
    Ennis, M.
    Fennema, E.
    Daksh, M.
    Sethi, S.
    Bauml, J. M.
    Garcia Campelo, M. R.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S103 - S104
  • [3] Enhanced vs Standard Dermatologic Management with Amivantamab-Lazertinib in Advanced NSCLC: Phase 2 COCOON Study
    Cho, B. C.
    Girard, N.
    Sauder, M. B.
    Feldman, J.
    Li, W.
    Bozorgmehr, F.
    Mak, M.
    Smith, J.
    Simoes, J.
    Mahadevia, P.
    Anderson, B. G.
    Romero, T.
    Xia, K.
    Wang, G.
    Murphy, S.
    Bauml, J. M.
    Spira, A. I.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S347 - S347
  • [4] Osimertinib as first-line therapy in advanced NSCLC: a profile of its use
    Scott L.J.
    Drugs & Therapy Perspectives, 2018, 34 (8) : 351 - 357
  • [5] MARIPOSA: Can Amivantamab and Lazertinib Replace Osimertinib in the Front-Line Setting?
    Brazel, Danielle
    Nagasaka, Misako
    LUNG CANCER-TARGETS AND THERAPY, 2024, 15 : 41 - 47
  • [6] Amivantamab plus lazertinib vs. osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer
    Hasan, Nazmul
    Nagasaka, Misako
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2025, 19 (03) : 223 - 232
  • [7] TAPO in first-line osimertinib therapy and continuation of osimertinib
    Mimura, Chihiro
    Kaneshiro, Kazumi
    Fujimoto, Shodai
    Dokuni, Ryota
    Iwamoto, Natsuhiko
    Matsumura, Kanoko
    Hatakeyama, Yukihisa
    Kono, Yuko
    Tachihara, Motoko
    THORACIC CANCER, 2023, 14 (06) : 584 - 591
  • [8] Correction to: Osimertinib as first-line therapy in advanced NSCLC: a profile of its use
    Lesley J. Scott
    Drugs & Therapy Perspectives, 2019, 35 : 50 - 50
  • [9] OSIMERTINIB MAY BE AN EFFECTIVE FIRST-LINE THERAPY IN EGFR-MUTANT NSCLC
    不详
    CANCER DISCOVERY, 2017, 7 (10) : 1061 - 1061
  • [10] Osimertinib Approved for First-Line Treatment in Metastatic NSCLC
    Schuyler, Devon
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (06) : 397 - 397
12345